Kevzara/sarilumab Cost, Side effects, Dosage, Uses for rheumatoid arthritis

The FDA granted approval of Kevzara to Regeneron Pharmaceutical, Inc., Rensselaer, NY, and Sanofi Winthrop Le Trait, Le Trait, France

US FDA approved new drug Kevzara that contains active pharmaceutical ingredient sarilumab for the treatment of  moderately to severely active rheumatoid arthritis in adult patients who are not responding to disease modifying anti-rheumatic drugs (DMARDs). FDA also indicated that this drug
can be used as single drug therapy or as combination therapy with other anti rheumatic drugs like methotrexate.

Rheumatoid arthritis (RA) is a life-time disease that most commonly affects movable joints of body. Primarily, it is an inflammatory disease manifested as joint swelling, severe pain, stiffness, increase friction and restricted mobility or movement. Major target areas of RA are wrist, hand and ankle joints. Patient may also feel lethargic, reduced energy level, restlessness and fatigue. Symptoms may become severe with passage of time. Treatment of  rheumatoid arthritis mostly consists of disease managements, physiotherapy, exercise and dietary control.

Exact underlying cause of  rheumatoid arthritis is not fully understood but many rheumatologists presume that genetic predisposition, immune system modulation and environmental factors play important role in the pathophysiology of rheumatoid arthritis. Initially, it starts with mild swelling around joints, feeling of joint stiffens right after sleeping and thickening of joint capsule. It is commonly observed that this majorly affects people having age 40 years or more. It has slow onset but longer duration like a chronic disease.

Kevzara/Sarilumab belong to a pharmacological class monoclonal antibody that binds with interleukin-6 receptor and causes inhibition of  IL-6 receptors. Interleukin-6 receptor plays important role in inflammatory response by mediating inflammatory substances such cytokines and
interleukins. Thus, inhibition of interleukin-6 receptor is reduces the process of inflammation of swelling.

Kevzara/sarilumab Cost, Side effects, Dosage, Uses for rheumatoid arthritis


Kevzara/sarilumab Side effects

According to data provided by health authorities this drug exhibit following side effects during clinical trials.

  • Neutopenia
  • Increased liver enzymes (ALT)
  • Reaction at injection site (Erythema)
  • Higher risk of respiratory tract infection
  • Anaphylactic reaction
  • Gastrointestinal perforation
  • Immunosuppression
  • Palpitation 
  • Headache


Kevzara/sarilumab Uses/Patient information

US FDA approved this drug for the treatment of  moderately to severely active rheumatoid arthritis in adult patients who are not responding to disease modifying anti-rheumatic drugs (DMARDs). Data regarding its usage in pregnancy is limited but during initial clinical trails it has been observed that it is actively transported across the placenta during the third trimester of pregnancy.

Kevzara/sarilumab Dosage

Drug is forlumated as 150mg/1.14ml and 200mg/1.14ml as a prefilled syringe. However, standard dosing frequency of this drug is 200mg administer subcutaneously after every two weeks (q2week). Dose titration must be kept in consideration in those patients who have hepatic or renal impairment
or have high ALT or platelets count.

Kevzara/sarilumab Cost

According to market survey this drug is currently not available at retail pharmacies because it is recently approved by FDA and is under manufacturing process. Once, it will be available at retail outlets we will let you know about the unit cost of drug and its dosage frequency.

Radicava/edaravone Cost, Side effects, Dosage, Uses for amyotrophic lateral sclerosis (ALS)

The FDA granted approval of Radicava to Mitsubishi Tanabe Pharma America, Inc.

US FDA approved new drug Radicava that contains active pharmaceutical ingredient edaravone for the treatment of amyotrophic lateral sclerosis (ALS). Radicava/edaravone is categorized as nootropic agent that helps in recovering cerebral damage or degeneration occurs as result of cerebral ischemia, cerebral infarction or any other disorder.

Amyotrophic lateral sclerosis (ALS) also termed as  Lou Gehrig's disease is a rare kind of neuronal problem associated with neuronal death. Neuron is basic unit of nervous system that regulates neuronal transmission required for coordination between body muscles and brain. Amyotrophic lateral sclerosis (ALS) most commonly affects motor neurons that controls body motor functions like driving, walking, speech, breathing etc.

Exact underlying cause is still unknown but many researchers assume that genetic predisposition is key factor in pathogenesis of such disorders. Some other causes that associated with Amyotrophic lateral sclerosis (ALS) are head injury, trauma and branched-chain amino acids enriched diet that induce cellular hyperexcitability. Lesions inside frontotemporal lobes may also be a cause of Amyotrophic lateral sclerosis (ALS).

Initially, it is started as muscular weakness and atropy (decrease in number of cells) . At this time symptoms are very insignificant to feel and patient may overlook these symptoms. when disease progress completely then patine may feel difficulty in walking, speech problems, difficulty with tasks requiring manual dexterity such as buttoning a shirt, writing, or turning a key in a lock may be experienced and muscle spasticity.

Radicava/edaravone Cost, Side effects, Dosage, Uses for amyotrophic lateral sclerosis (ALS)


Radicava/edaravone Side effects


According to data provided by health authorities following side effects were observed during clinical trials

  •     Rash
  •     Hives
  •     Swelling
  •     Shortness of breath
  •     Anaphylaxis
  •     Sodium bisulfite induced allergy
  •     Bruising
  •     Gait disturbance
  •     Nervousness
  •     Loss of appetite
  •     Sleep disturbance

Radicava/edaravone Uses


US FDA approved this drug for the treatment of amyotrophic lateral sclerosis (ALS) to show to slow down functional decline. Radicava/edaravone is free-radical scavenger that is aimed to suppress oxidative degeneration which is a major factor in amyotrophic lateral sclerosis (ALS).

Radicava/edaravone Dosage


This drug is formulated in a single dose polypropylene bag with potency of 30mg/100ml. However, standard dosage frequency of this drug is 60mg as intravenous infusion (IV) over 60 minutes once a day for 14 days followed by a 14-day drug-free period.

Radicava/edaravone Cost


According to market survey this drug is currently not available at retail pharmacies because it is recently approved by FDA and is under manufacturing process. Once, it will be available at retail outlets we will let you know about the unit cost of drug and its dosage frequency. 

Tymlos/Abaloparatide Cost, Side effects, Dosage, Uses for postmenopausal osteoporosis

US FDA granted approval of Tymlos to Radius Health, Inc.

US FDA approved new medicine Tymlos that contains active pharmaceutical ingredient abaloparatide for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Tymlos/Abaloparatide is parathyroid hormone related protein (PTHrP) and is anabolic agent used to increase bone densification.

Tymlos/Abaloparatide is analogus drug that binds with parathyroid hormone 1 receptor  (PTH1R) which results in activation of Cyclic adenosine monophosphate (cAMP). Cyclic adenosine monophosphate is important compound for intracellular signal transduction in many biological process. This cAMP increase bone densification and mineralization (BMD and BMC) resulting in increase bone strength .

Osteoporosis is worldwide common disease that increase the risk of fractures and bone deformity due to bone demineralization and fragility.  Most commonly affected bones are back bones, forearm bones, hip bone etc. Persistent pain may hinder to carry out routine activities. Osteoporosis symptoms are not obvious initially but later on excessive demineralization may lead to fractures.

Being old, is a major risk factor for osteoporosis. This risk may increase two times in women due to hormonal imbalance after age 40's of 50's. Certain diseases like diabetes, adrenal insufficiency, crohn's disease, coeliac disease, malabsorption disturb calcium phosphorus balance in the body that may lead to osteoporosis if persist for a long term.

TymlosAbaloparatide Cost, Side effects, Dosage, Uses for postmenopausal osteoporosis



Tymlos/Abaloparatide Side effects


According to data provided by health authorities this drug exhibit following side effects during clinical trials
  • Hypercalciuria
  • Dizziness
  • Nausea
  • Headache 
  • Palpitations
  • Fatigue
  • Upper abdominal pain
  • Vertigo
US FDA also instruct for box warning that tymlos/abaloparatide caused a dose-dependent increase in the incidence of osteosarcoma (a malignant bone tumor) in male and female rats; this effect was observed at systemic exposures to abaloparatide ranging from  4-28 times the exposure in humans receiving the 80-mcg dose.


Tymlos/Abaloparatide Uses/Prescribing Information


US FDA approved new medicine Tymlos that contains active pharmaceutical ingredient abaloparatide for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Tymlos/Abaloparatide is parathyroid hormone related protein (PTHrP) and is anabolic agent used to increase bone densification.

Tymlos/Abaloparatide Dosage


This drug is formulated as 80mcg/40mcL (available as a pre-filled pen that delivers 30 daily doses of 80mcg). However, standard dosage frequency is 80mcg subcutaneously once a day. Dose tit-ration should be considered in patient having liver or kidney impairment.

Tymlos/Abaloparatide Cost


Tymlos/Abaloparatide is now available in market. Each pre-filled pen of Tymlos/Abaloparatide has drug voume of 1.56ml. Approximate cost of each pre-filled pen of Tymlos/Abaloparatide is about 1600$ to 1800$. This price may variate with the passage of time so, make it confirm by visiting your nearby pharmacy before purchasing.

Imfinzi/Durvalumab Cost, Side Effects, Dosage, Uses for Urothelial Carcinoma

US FDA granted approval of Imfinzi to AstraZeneca UK Limited.

US FDA approved new medicine Imfinzi that contains active pharmaceutical ingredient durvalumab for the treatment of metastatic urothelial carcinoma that is not responding to platinum containing chemotherapeutic drugs. Imfinzi/Durvalumab belongs to a pharmacological class termed as monoclonal antibodies that targtet programmed death ligand-1 (PD-L1).

Moreover, US FDA approved this indication under accelerated approval pathway based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Urothelial carcinoma (Transitional cell carcinoma) is type of carcinoma that affects urinary tract most likely ureter, urethra and urachus. It is highly progressive form of malignant tumor that arises from transitional epithelium (Urothelium). This type of tumor readily spread to nearby tissues and is difficult to eradicate completely. Urothelial carcinoma has high recurrence rate even after surgical resection. Symptoms of urothelial carcinoma are not obvious and vary from patient to patient. However, some pre-defined symptoms are small amount of blood in urine, consistent pain in back due to tumor pressure, weakness, painful micturition , unexplained weight loss.

Exact underlying mechanism is not fully understood but many scientist and researchers presumed that genetic predisposition, smoking, being old age, exposures to chemicals in chemical processing industries like paints, petroleum products, toxic compounds like aniline double the risk of urothelial carcinoma.In some, patients it is also associated with prostate gland. Certain drugs like cyclophosphamide and chronic bladder infections are also known to cause urothelial carcinoma.


ImfinziDurvalumab Cost, Side Effects, Dosage, Uses for Urothelial Carcinoma



Imfinzi/Durvalumab Side effects


According to data provided by health authorities this drug showed following side effects during clinical trials


  • Fatigue
  • Headache
  • Muscular pain
  • Loss of appetite 
  • Drug induced colitits 
  • Increase risk of infection
  • Edema
  • Colitis
  • Hypersensitivity reactions
  • Rashes
  • Infusion related reactions
  • Mild fever


Imfinzi/Durvalumab Uses/Patient Information


US FDA approved Imfinzi/Durvalumab for the treatment of  advance progressive urothelial carcinoma that is not responding to other chemotherapeutic drugs like platinum containing drugs. This drug can also be used in combination with other chemotherapeutic agents to get more efficacious results. Moreover, initial studies conducted by health authorities also suggest that imfinzi/durvalumab may pose risk to fetal development so it should be avoided in pregnancy.

Imfinzi/Durvalumab Dosage


Imfinzi is formulated as 120mg/2.4mL (50mg/mL) single-dose vial and 500mg/10mL (50mg/mL) single-dose vial. However, standard dosage frequency of imfinzi is 10mg/Kg intravenously via infusion over 1 hr. In case of toxicity or severe adverse effects like pneumonitis, hepatitis or colitis withhold or discontinue drug to manage such adverse effects.

Imfinzi/Durvalumab Cost


According to market survey this drug is currently not available at retail pharmacies because it is recently approved by FDA and is under manufacturing process. Once, it will be available at retail outlets we will let you know about the unit cost of drug and its dosage frequency.

Brineura/cerliponase alfa Cost, Side effects, Dosage, Uses for Batten disease

The FDA granted approval of Brineura to BioMarin Pharmaceutical Inc

US FDA approved new medicine Brineura that contains active pharmaceutical ingredient cerliponase alfa for the treatment of specific type of batten disease. This first drug approved by US FDA to reduce the severity of symptoms like impaired walking ability in pediatric patients having age less than 3 years or more suffering from late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase-1 (TPP1) deficiency.

Batten disease is extremely rare kind of disease and characterized by fatal autosomal recessive neuro-degenerative disorder. It is kind of neuro-degenerative disorder and placed in a group of disorders termed as  neuronal ceroid lipofuscinoses (NCLs). So far 20 genes have been identified that have linked with batten disease out of which type 3 (CLN3) has high incidence rate.

Major sign and symptoms of batten disease include vision difficulties, mood changes, variation in behavior, mental retardation, speech difficulties, seizures and poor circulation of blood in extremities. It has been observed that in females symptoms develops later than in males but their survival life span is shorter than males. Batten disease is simply a genetic disorder so, people having batten disease in their family history are more prone to batten disease.

Brineura/cerliponase alfa Cost, Side effects, Dosage, Uses for Batten disease


Brineura/cerliponase alfa Side effects

According to data provided by US FDA drug exhibit following side effects during clinical trials
  • Changes in ECG waves
  • Decreased heart rate
  • Anaphylaxis
  • Nausea 
  • Vomiting
  • Seizures
  • hemorrhage
  • Rash
  • Increase in CSF protein
  • Infection at injection  site

Brineura/cerliponase alfa Uses or Patient Information


This first drug approved by US FDA  for the treatment of specific form of batten and to slow down the loss of walking ability (ambulation) in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase-1 (TPP1) deficiency.

Brineura/cerliponase alfa Dosage


This drug is formulated as intraventricular injection administered via intraventricular administration kit. This kit includes

  • Two 20-mL syringes
  • Two syringe needles (21 ga, 25.4 mm)
  • One extension line
  • One infusion set with 0.2 micron inline filter
  • One port needle (22 ga, 16 mm)

Standard dosage frequency of Brineura is 300mg by intraventricular infusion once every other week in patients having age 3 years or more. Drug Safety profile has not yet evaluated in patents having age less than 3 years.

Brineura/cerliponase alfa Cost


According to market survey this drug is currently not available at retail pharmacies because it is recently approved by FDA and is under manufacturing process. Once, it will be available at retail outlets we will let you know about the unit cost of drug and its dosage frequency.

Rydapt/midostaurin Cost, Side effects, Dosage, Uses for acute myeloid leukemia (AML)

The FDA granted the approval of Rydapt to Novartis Pharmaceuticals Corporation. 

US FDA approved new medicine Rydapt that contains midostaurin as an active pharmaceutical ingredient for the treatment of acute myeloid leukemia in those adults who have fms like tyrosine kinase 3 (FLT-3) mutation. FDA indicated the usage of this drug along LeukoStrat CDx FLT3 ( Mutation detection Assay used to detect the FLT3 mutation in patients with AML).

Acute myeloid leukemia (AML) is a type of cancer of myeloid cells characterized by instant proliferation of abnormal white blood cells (WBC's). Mortatlity rate of Acute myeloid leukemia (AML) is 1.2% of cancer deaths in the United States. Though, it is rare disease but middle age group is most commonly affected by AML. Acute myeloid leukemia (AML) has several types It is presumed that regular exposure to chemical agents aromatic compounds like benzene, ionizing agents, radicals, halogens and oxidative agents are major risk factors that play important role in pathogenesis of Acute myeloid leukemia (AML). Other risk factors include genetic predisposition, blood disorders, viral infections etc.

Symptoms of Acute myeloid leukemia (AML) include flu like symptoms, restlessness, mild fever, weight loss, loss of appetite, gums swelling, enlarged spleen, internal hemorrhage, petechiae, frequent infections. In some cases Lymph node swelling may also occur but is rare. Patient having age less than 50 years have more survival rate than those having age more than 60 years. 


Rydapt/midostaurin Cost, Side effects, Dosage, Uses for acute myeloid leukemia (AML)

Rydapt/midostaurin Side effects


According to data provided by US FDA this drug exhibit following side effects during clinical trials


  • Drug induced neutropenia
  • Nausea 
  • Vomiting
  • Mucous membrane swelling
  • Diarrhea
  • fatigue
  • abdominal pain
  • Constipation
  • Fever
  • muscular pain
  • shortness of breadth
  • Upper respiratory tract infections
  • Asthenia
  • Loss of appetite

Rydapt/midostaurin Uses or Patient Information


US FDA assigned Rydapt as breakthrough therapy for the treatment of acute myeloid leukemia (AML) in those patients in which fms like tyrosine kinase 3 (FLT-3) mutations have identified. This drug can be used with other chemotherapeutic agents. Additionally, US FDA also indicated the usage of this drug with LeukoStrat CDx FLT3 ( Mutation detection Assay used to detect the FLT3 mutation in patients with AML).

Rydapt/midostaurin Dosage



Rydapt/midostaurin is formulated  as 25mg tablet for oral administration. It is dosage frequency is 50mg orally (PO) twice a day (BID). This drug may also be used in combination with other chemotherapeutic agents like cytarabine and daunorubicin.

Rydapt/midostaurin Cost

Rydapt/midostaurin is now available in market. Each pack of Rydapt/midostaurin contains 28 capsules (28's) with potency of 25mg. Approximate cost of each pack of Rydapt/midostaurin is 3800$ to 4000$. This price may variate with the passage of time so, make it confirm by visiting your nearby pharmacy before purchasing.

Ingrezza/Valbenazine Cost, Side effects, Dosage, Uses for Tardive Dyskinesia

The FDA granted approval of Ingrezza to Neurocrine Biosciences, Inc.

US FDA approved new drug Ingrezza that contains valbenazine as an active pharmaceutical ingredient for the treatment of tardive dyskinesia in adults. This first kind of therapy approved by US FDA as a licensed treatment for tardive dyskinesia. This drug belongs to therapeutic class termed as  vesicular monoamine transporter 2 (VMAT2) inhibitors.

Tardive dyskinesia (TD) is a severe and incurable form of dyskinesia characterized by repetitive involuntary body movements. It is termed as tardive because movements in this type of disorder are slow or belated onset. One of the major cause of this disorder is abusive use of anti psychotic drugs for a long term.

Exact underlying mechanism is still uncleared to somehow but many researcher and health care providers proposed over used of anti-psychotic drugs, smoking, neuro-degeneration, genetic predisposition, increase age are those factors that have strong correlation with this disease. Common manifestation of tardive dyskinesia are grimacing, eye blinking, lip smacking, tongue movements and lip puckering. Rapid involuntary movements of extremities may also occur. Respiratory problems like difficult breathing, grunting and respiratory depression may feel by patient suffering
tardive dyskinesia.

Ingrezza/Valbenazine is VMAT-2 inhibitor.It works by reducing the dopamine release into synaptic cleft by inhibiting VMAT2 at pre-synaptic area. VMAT2 are responsible for dopamine loading into synaptic vesicles to release them into synaptic cleft. Thus inhibition of VMAT2 creates reversible reduction of dopamine in synaptic cleft.


IngrezzaValbenazine Cost, Side effects, Dosage, Uses for Tardive Dyskinesia




Ingrezza/Valbenazine Side Effects


According to data provided by health authorities drug exhibit moderate to severe kind of side effects during clinical trials. These side effects were

  • Sleepiness 
  • Palpitation
  • Nervousness
  • Headache
  • Prolongation of QT interval
  • Cardiac Arrhythmia
  • Mental  


Ingrezza/Valbenazine Uses/Patient Information


This is the first drug approved by US FDA  (licensed treatment) for the treatment of tardive dyskinesia in adults. In pediatric patients safety profile of this drug has not yet been evaluated.


Ingrezza/Valbenazine Dosage


Standard dosage frequency of this drug is 40mg once a day but in some cases dosage frequency may increased up-to  80mg once a day orally after first week of therapy. Dose adjustment should be considered in case of liver or hepatic impairment. 


Ingrezza/Valbenazine Cost


Ingrezza 40mg capsules are now available in market. Each of pack of Ingrezza 40mg contains 30 capsules (30's) with an estimated average cost of 5000$ - 6000$. Ingrezza 80mg capsules are not yet avialble in market. This price may variate with the passage of time so, make it confirm by visiting your nearby pharmacy before purchasing. 

Ocrevus/Ocrelizumab Cost, Side effects, Dosage, Uses for Multiple Sclerosis

The FDA granted approval of Ocrevus to Genentech, Inc.

US FDA approved Ocrevus that contains active pharmaceutical ingredient ocrelizumab ( monoclonal antibody) for the treatment episodal or recurring form of multiple sclerosis in adult patients. This is first drug approved for primary progressive multiple sclerosis by US FDA. This drug is administered in parenteral dosage form under the supervision of medically trained professional.

Multiple sclerosis (MS) is a kind of neuro-degenerative disease in which demyelination of nerve cells occurs. This damage imparts long lasting effects and impairs co-ordination system. Common manifestations of multiple sclerosis are vision disturbance, deceased muscle tone, difficulty in body movements, impaired sensation etc.

The exact etiological cause of multiple sclerosis is still unknown to somehow but many researchers believed that auto-immune disorders, impaired myelination, genetic predisposition and viral infections act as triggering factors in the pathogenesis of multiple sclerosis. There is no single magic bullet that can cure multiple sclerosis but it can be managed by utilizing combination of therapies. Multiple sclerosis is common in among all populations without regard to age and gender.

Ocrevus/Ocrelizumab is a monoclonal antibody used as immunotherapy. It is termed as anti-CD20 monoclonal antibody that targets CD20 marker on B lymphocytes.

OcrevusOcrelizumab Cost, Side effects, Dosage, Uses for Multiple Sclerosis


Ocrevus/Ocrelizumab Side effects

According to data obtained from health authorities drug induced side effects were moderate to severe during clinical trails. These side effects are

  • Hypersensitivity (Anaphylaxis)
  • Infusion related reactions
  • Generalized weakness
  • Dizziness
  • Hypotension
  • Rashes
  • Shortness of breath
  • Respiratory tract irritation
  • Increased risk of malignancy

Ocrevus/Ocrelizumab Uses or Patient Information

Currently, there are number of therapies available for the treatment of multiple sclerosis but US FDA approved Ocrevus for the treatment of episodal or recurring for of multiple sclerosis that is less responsive to other drugs. This first drug approved by US FDA for primary progressive multiple sclerosis.

Ocrevus/Ocrelizumab Dosage

This drug is formulated as 30mg/mL (300mg/10mL single-dose vial). However, standard dosage frequency of this drug is 300mg intravenously (IV) for the first time then after 2 weeks administer same dose. For subsequent doses inject 600mg after every 6 months.

Ocrevus/Ocrelizumab Cost

This drug is administered by your healthcare practitioner (HCP), which usually means:
  • It may comes under special items category.
  • You cannot fill this prescription in a regular pharmacy. Your doctor, hospital, or clinic will provide this  medication because of possible complications or other issues.
  • This drug is likely to be covered under your medical benefit if you have insurance.

Dupixent/dupilumab Cost, Side effects, Dosage, Uses for Eczema

The FDA granted the approval of Dupixent to Regeneron Pharmaceuticals, Inc.

US FDA approved Dupixent that contains active pharmaceutical ingredient dupilumab for the treatment of atopic dermatitis also known as eczema. This drug is administered in the parenteral dosage form to treat eczema that is not responsive to topical therapy or severe kind of eczema.

Ezema or dermatitis is a group of skin disorders that occur due to autoimmune disease, allergic reaction, skin inflammation or infection. Some common manifestations of eczema are inflammation of epidermis, blistering, skin thickening, redness of skin, severe itching and burning sensation. Most commonly affected areas are hand, foot and arms but it might affect the whole body in some cases. 

As far as etiology is concerned, many researchers believe that environmental allergens, genetic predisposition, immune system modulation and poor venous return act as triggering factors in pathogenesis of eczema but still the exact underlying cause is not yet fully known. Allergic dermatitis or eczema is most common form eczema that is common among all populations without regard to age and gender.

Dupixent/dupilumab is a monoclonal antibody used as immunotherapy. Pharmacologically, it has affinity to bind  with sub-part of interleukin-4 receptor (IL-4Rα). It causes inhibition or modulation of IL-4Rα that plays important role in inflammatory pathway and release of inflammatory mediators. In such way Dupixent reduces inflammation and severity of disease. 


Dupixent/dupilumab Cost, Side effects, Dosage, Uses for Eczema



Dupixent/dupilumab Side effects

According to According to data obtained from health authorities drug induced side effects were moderate to severe during clinical trails. Detail of these side effects are 

  • Hypersensitivity (anaphylaxis)
  • Corneal Inflammation (keratitis)
  • Scleral inflammation 
  • Conjuctivitis
  • Pain at injection site
  • Itching
  • Skin redness
  • Blisters or cold sores

Dupixent/dupilumab Uses or Patient Information

There are number topical therapies available for eczema treatment but US FDA approved Dupixent as breakthrough therapy due to promising result in eczema patients. US FDA approved this drug for eczema that is less responsive to topical therapy or severe kind of eczema.

Dupixent/dupilumab Dosage

Standard dosage strength of this drug is 300mg/2ml in a single dose Pre-filled syringe. Regular dosage frequency of this drug is 600mg (two injections of 300mg) subcutaneously (SC) in first week and then 300mg (1 injection) every other week.

Dupixent/dupilumab Cost

This drug is now available in market. According to market survey cost of single pack of dupixent ranges from 1400$ - 1600$. Each pack contains 2 pre-filled syringes of dupixent 150mg/mlThis price may variate with the passage of time so, make it confirm by visiting your nearby pharmacy before purchasing.  

Bavencio/avelumab Cost, Side effects, Dosage, Uses for skin cancer

The FDA granted accelerated approval of Bavencio to EMD Serono Inc.

 US FDA approved new drug Bavencio that contains active pharmaceutical ingredient avelumab therapeutically categorized as anti-PD-L1 IgG1 monoclonal antibody for the treatment of merkel cell carcinoma (MCC) a rare kind of skin carcinoma in adults and pediatrics.This is first kind of treatment as immunotherapy approved by US FDA for the treatment of MCC.

Though, merkel cell carcinoma is a rare kind of skin carcinoma but it is one of the most aggressive form of skin disorders. Merkel cell carcinoma is also characterized as cutaneous APUDoma. Exact underlying cause is still unclear to somehow but many researchers strongly believed that merkel cell polomavirus (MCV) is one of the leading causes of MCC. According to a statistics about 80% of merkel cell carcinoma are somewhere connected with polyomavirus while 20% of MCC cases are still unknown as  far as the underlying mechanism is concerned. This virus was first discovered in 2008 by a team of scientists at University of Pittsburgh.

Clinically this carcinoma is classified as neuroendocrine tumor and common manifestations of this tumor are small painless nodular mass projected upward and can be seen through naked eye. Mot of the times,they are brown to reddish or flesh colored tumors ranges from 0.5cm to 5cm in diameter.

Bavencio/avelumab Cost, Side effects, Dosage, Uses for skin cancer

Bavencio/avelumab Side effects

According to data obtained from health authorities this drug exhibit some side effects during clinical trails there were mild to moderate or some were severe kind of reactions. Detail of these side effects is as follows

  • Asthenia (general weakness)
  • Muscular aches
  • Nausea
  • Vomiting
  • Loss of appetite
  • Swelling in extremities
  • Edematous condition
  • Immune system hypersensitivity
  • liver inflammation
  • colitis
  • Endocrine disorders
  • Infusion related reactions

Bavencio/avelumab Uses/Prescribing Information

US FDA approved this drug for the treatment of rare but highly progressive for of skin carcinoma known as metastatic merkel cell carcinoma in adults and children having age 12 years old or more than that. This is first kind of immunotherapy approved by US FDA for the treatment of MCC.

Bavencio/avelumab Dosage

Bavencio/avelumab is administered in the form parenteral solution (intravenously). It's standard dosage frequency is 10mg/Kg after every 2 weeks in adults and children having age 12 years or more. This therapy continues for a long term to revert the progression of disease. In case of severe side effects or unacceptable toxicity drug should be discontinued and immediately consult with your health care provider.

Bavencio/avelumab Cost

This drug is administered by your healthcare practitioner (HCP), which usually means:
  • It may comes under special items category.
  • You cannot fill this prescription in a regular pharmacy. Your doctor, hospital, or clinic will provide this  medication because of possible complications or other issues.
  • This drug is likely to be covered under your medical benefit if you have insurance.